Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1940 1
1947 3
1950 1
1952 1
1955 1
1966 1
1972 1
1974 1
1975 1
1978 1
1985 1
1987 2
1989 6
1990 2
1991 6
1993 3
1994 4
1995 1
1996 5
1997 7
1998 7
1999 7
2000 7
2001 13
2002 11
2003 6
2004 10
2005 6
2006 10
2007 6
2008 5
2009 8
2010 2
2011 2
2012 6
2013 5
2014 5
2015 8
2016 14
2017 13
2018 13
2019 15
2020 15
2021 14
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

241 results
Results by year
Filters applied: . Clear all
Page 1
Vascular access for hemodialysis: A perpetual challenge.
Murea M, Geary RL, Davis RP, Moossavi S. Murea M, et al. Among authors: geary rl. Semin Dial. 2019 Nov;32(6):527-534. doi: 10.1111/sdi.12828. Epub 2019 Jun 17. Semin Dial. 2019. PMID: 31209966 Free PMC article. Review.
Pharmacology of Antisense Drugs.
Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. Bennett CF, et al. Among authors: geary rs. Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:81-105. doi: 10.1146/annurev-pharmtox-010716-104846. Epub 2016 Oct 10. Annu Rev Pharmacol Toxicol. 2017. PMID: 27732800 Review.
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E. Witztum JL, et al. Among authors: geary rs. N Engl J Med. 2019 Aug 8;381(6):531-542. doi: 10.1056/NEJMoa1715944. N Engl J Med. 2019. PMID: 31390500 Clinical Trial.
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S. Graham MJ, et al. Among authors: geary rs. N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24. N Engl J Med. 2017. PMID: 28538111 Free article. Clinical Trial.
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, Figueroa AL, Piscitelli P, Singleton W, Witztum JL, Geary RS, Tsimikas S, O'Dea LSL; Vupanorsen Study Investigators. Gaudet D, et al. Among authors: geary rs. Eur Heart J. 2020 Oct 21;41(40):3936-3945. doi: 10.1093/eurheartj/ehaa689. Eur Heart J. 2020. PMID: 32860031 Free PMC article. Clinical Trial.
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Viney NJ, et al. Among authors: geary rs. Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21. Lancet. 2016. PMID: 27665230 Clinical Trial.
241 results